Genomma Lab Internacional, S.A.B. de C.V.

DB:GEKA

墨西哥 / 保健 / 製藥

綜觀

股息

5 年 DCF EBITDA 退出價

股價

1.11 EUR

公允價值

1.66 EUR

Metrics	Range	Conclusion
Discount Rate	9.3% - 8.3%	8.8%
Terminal EBITDA Multiple	5.4x - 7.4x	6.4x
Fair Value	€1.43 - €1.91	€1.66
Upside	29.2% - 71.7%	50.0%

7.3%

Revenue 5y CAGR

24.3%

5y Avg EBITDA Margin

14.5%

Unlevered FCF 5y CAGR

5-Year DCF Model: EBITDA Exit

股價

1.11 EUR

公允價值

1.66 EUR

看漲

50.0%

Revenue and EBITDA

CapEx

Working Capital

D&A

Tax Rate

Discount Rate

Terminal Value


Select Revenue and EBITDA Forecast

(MXN in millions)		Input Projections
Fiscal Years Ending	Dec-24	Dec-25	Dec-26	Dec-27	Dec-28	Dec-29

Revenue	18,607	19,739	20,357	23,782	25,522	26,415
% Growth	13.0%	6.1%	3.1%	16.8%	7.3%	3.5%

EBITDA	4,342	4,728	4,903	5,837	6,262	6,481
% of Revenue	23.3%	24.0%	24.1%	24.5%	24.5%	24.5%

支援算式

Calculation of Free Cash Flow

Discounting Periods

Discounting Factors

Calculation of Enterprise Value

Equity Waterfall

Historical Financials

Current Trading Multiples


Calculation of Free Cash Flow

Projected Unlevered Cash Flow
(MXN in millions)		Dec-25	Dec-26	Dec-27	Dec-28	Dec-29

EBITDA		4,728	4,903	5,837	6,262	6,481
Other Income / (Exp)		0	0	0	89	0
D&A		(350)	(329)	(13)	(13)	(753)

EBIT		4,379	4,575	5,824	6,337	5,728
Pro forma Taxes		(1,576)	(1,647)	(2,097)	(2,281)	(2,062)
NOPAT	2,549	2,802	2,928	3,727	4,056	3,666

Capital Expenditures	(271)	(241)	(248)	(196)	(199)	(287)
NWC Investment	(681)	(360)	(197)	(1,089)	(554)	(284)
(+) D&A	360	350	329	13	13	753

Free Cash Flow	1,957	2,551	2,812	2,454	3,317	3,847
% Growth		30%	10%	-13%	35%	16%

載入錯誤

Genomma Lab Internacional, S.A.B. de C.V.

DB:GEKA

墨西哥 / 保健 / 製藥

5 年 DCF EBITDA 退出價